NCT04256421 2026-04-03
SKYSCRAPER-02
Hoffmann-La Roche
Phase 3 Completed
Clinical Trials
104 trialsNCT04063163 2025-12-09
A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC
Shanghai Henlius Biotech
Phase 3 Completed
NCT05664971 2025-12-02
JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 1/2 Completed
NCT03132532 2025-11-25
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
Phase 2 Completed
NCT03041311 2025-09-25
Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC
G1 Therapeutics, Inc.
Phase 2 Completed
NCT04924101 2025-07-23
KEYNOTE-B99
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03382561 2025-07-03
Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02262325 2025-06-12
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04774380 2025-05-23
LUMINANCE
AstraZeneca
Phase 3 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT04005716 2025-02-28
Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
BeiGene
Phase 3 Completed
NCT05309629 2025-01-17
Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 2 Completed
NCT03509012 2025-01-14
CLOVER
AstraZeneca
Phase 1 Completed
NCT04712903 2025-01-07
CANTABRICO
AstraZeneca
Phase 3 Completed
NCT03432598 2024-10-23
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
BeiGene
Phase 2 Completed
NCT02815592 2024-09-04
Trial of BMS-986012 in Combination With Platinum and Etoposide
Bristol-Myers Squibb
Phase 1 Completed
NCT03850067 2024-08-26
A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer
Celgene
Phase 1 Completed
NCT04622228 2024-07-29
Match
Hoffmann-La Roche
Phase 2 Completed
NCT04028050 2024-07-16
MAURIS
Hoffmann-La Roche
Phase 3 Completed
NCT04730999 2024-07-05
CeLEBrATE
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2 Completed
NCT05116007 2024-05-31
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
Akeso
Phase 1 Completed
NCT04878016 2024-02-02
A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC
Lee's Pharmaceutical Limited
Phase 3 Completed
NCT02580994 2023-12-11
REACTION
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00869752 2023-08-04
MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
NCT02763579 2023-07-28
IMpower133
Hoffmann-La Roche
Phase 3 Completed
NCT05026593 2023-07-19
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT00057837 2023-07-05
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03214003 2023-06-22
TRISS
Peking University Cancer Hospital & Institute
Phase NA Completed
NCT01642251 2023-05-06
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT03066778 2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00025272 2021-09-09
Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00826644 2021-08-09
COMBAT
Chonnam National University Hospital
Phase 3 Completed
NCT01840579 2021-06-22
MK-3475-011
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01076231 2021-05-17
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00003606 2021-02-21
Combination Chemotherapy in Treating Patients With Extensive Stage Small Cell Lung Cancer
UNICANCER
Phase 3 Completed
NCT00003860 2021-02-21
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer
UNICANCER
Phase 2 Completed
NCT03059667 2021-02-10
Immunotherapy as Second-line in Patient With Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Completed
NCT00887159 2021-01-05
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
National Cancer Institute (NCI)
Phase 2 Completed
NCT01958372 2020-11-23
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT02499770 2020-08-21
Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)
G1 Therapeutics, Inc.
Phase 1/2 Completed
NCT01450761 2020-07-08
Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Bristol-Myers Squibb
Phase 3 Completed
NCT02289690 2020-05-14
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
AbbVie
Phase 1/2 Completed
NCT00589056 2020-04-24
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Phase 1/2 Completed
NCT00613626 2020-02-11
Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer
Hoosier Cancer Research Network
Phase 2 Completed
NCT00388960 2019-11-19
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
Celgene
Phase 2 Completed
NCT02949895 2019-08-12
Study of BMS-986012 in Subjects With Small Cell Lung Caner
Bristol-Myers Squibb
Phase 1 Completed
NCT00554463 2019-05-29
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 2 Completed
NCT00926640 2018-10-19
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00045162 2018-07-31
S0124: Cisplatin Combined With Irinotecan or Etoposide For Extensive-Stage Small Cell Lung Cancer
SWOG Cancer Research Network
Phase 3 Completed